Research
Hormonal
The weight loss benefit of tirzepatide over semaglutide is significantly attenuated or absent in patients with type 2 diabetes compared to those without diabetes.
For patients with diabetes, the weight loss advantage of tirzepatide over semaglutide seen in non-diabetics may not be present. Consult your doctor to manage expectations regarding weight loss if you have diabetes.
ModerateQualifiesMEDIUM confidence
In patients with diabetes, tirzepatide was not associated with weight loss (0.4% additional weight loss; 95% CI (cid:1)2.7%, 1.8%, p = 0.70) relative to semaglutide.
Why this rating
Retrospective cohort study with potential confounding.
Source
Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting
Huong Trinh et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16343
cohort · n=945Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →